DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Rini BI, Pal SK, Escudier BJ. et al.
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
Lancet Oncol 2020;
21: 95-104
DOI: 10.1016/s1470-2045(19)30735-1.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.